BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Increased by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. increased its stake in BioCryst Pharmaceuticals by 39.9% in Q1, acquiring 38,846 additional shares, bringing its total ownership to 136,103 shares valued at $1,021,000.
• In its latest earnings report, BioCryst Pharmaceuticals beat expectations with a $0.15 EPS and revenue of $163.35 million, representing a 49.5% year-over-year increase.
• BioCryst Pharmaceuticals has received several upgrades from analysts, with a majority rating of "Moderate Buy" and an average price target of $16.70.

Graham Capital Management L.P. grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 39.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 136,103 shares of the biotechnology company's stock after purchasing an additional 38,846 shares during the period. Graham Capital Management L.P. owned about 0.07% of BioCryst Pharmaceuticals worth $1,021,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $80,000. Mariner LLC grew its position in BioCryst Pharmaceuticals by 32.1% in the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,224 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in BioCryst Pharmaceuticals by 84.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 23,083 shares of the biotechnology company's stock worth $174,000 after buying an additional 10,583 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $748,000. Finally, Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after purchasing an additional 143,986 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on BCRX. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. Wedbush raised their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Finally, Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded down $0.08 during midday trading on Monday, reaching $8.20. 1,305,851 shares of the company were exchanged, compared to its average volume of 3,699,974. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -45.58, a price-to-earnings-growth ratio of 1.88 and a beta of 1.13. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.01 and a 1-year high of $11.31. The stock's 50-day simple moving average is $8.52 and its 200 day simple moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same period in the previous year, the firm earned ($0.06) earnings per share. BioCryst Pharmaceuticals's revenue was up 49.5% on a year-over-year basis. On average, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.